Global biosimilars/follow-on-biologics market (Technology, Types, Applications, Services and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 Biosimilars or follow-on-biologics are the “copied� version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market. Most of the blockbuster patents will expire by the end of 2014, which would provide a competitive edge to local pharmaceutical manufacturers over the global players. For instance, patents for insulin glargine will expire by the end of this year, which would give an opportunity for the growth of insulin biosimilars market. Global biosimilars/follow-onbiologics market accounted for $1,358 million in 2013 and it is anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from 2014 to 2020. Regulations for biosimilars plays a vital role in maintaining the viability and balance between original and biosimilar products. Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating the biosimilars market. Regulations in the European union are considered benchmark around the world, as the guidelines proposed are most stringent for validation and commercialization of biosimilars. High profitability is the attractive aspect that is enticing companies to invest in the biosimilars industry. Browse the report with TOC at http://www.alliedmarketresearch.com/biosimilars-market Geographically, Biosimilars market is segmented into North America, Europe, Asia-Pacific and LAMEA. Due to favorable regulatory policies designed by the European Medical Association, the European market has been maximizing on the biosimilars market. Asia-Pacific and LAMEA market would witness a substantial rise in the use of biosimilars, as the demand for cost effective treatment is growing due to the prevalence of chronic diseases. Collaboration with local players would be a key opportunity that could be fully explored by the biosimilars manufacturers in developing economies. Many companies such as Amgen and Novartis are collaborating with Asian players to gain a foothold in the biopharmaceutical market. Europe was the first region to draft guidelines for approval of biosimilars in 2006. Nevertheless, in 2008, the first biosimilars version of Granulocyte colony-stimulating factor (G-CSF) was introduced in the European Union under the regulatory guidance of European Medical Association (EMA). Currently, there are three biosimilar versions of G-CSF available in the European market, namely Ratiograstim/Tevagrastim/Biograstim, Zarzio/Filgrastim Hexal and Nivestim/Pliva/Mayne filgrastim. Adding to the G-CSF biosimilars, the insulin biosimilars also showcase tremendous potential in the future.
To make an enquiry before purchasing the http://www.alliedmarketresearch.com/purchase-enquiry/162
report,
visit
at
Key Benefits The study is segmented in a strategic divisions to gain deeper insights into the market dynamics and understand the competitive environment of the overall market Financial market forecast is provided for the next eight years by considering 2013 as the base year Comprehensive and quantitative data about changing market trends, intensifying competition and opportunities in biosimilars market are provided to make better business decisions Porter’s Five Forces model and SWOT analysis of the overall market is provided to help stakeholders gain strategic insights of the market Deep dive analysis of key market players and strategies adopted by them are expounded to provide valuable information on the top contenders in the market Identification of key investment pockets for the biosimilars market is strategically dealt to assist the stakeholders Key Deliverables Global biosimilars/follow-on-biologics market is categorized into technology, product types, applications, services and geography. MARKET BY TECHNOLOGY • •
Monoclonal Antibodies (MAb) Technology Recombinant DNA Technology (rDNA technology)
•
Nuclear magnetic resonance (NMR) technology
•
Chromatography
•
Electrophoresis
•
Mass Spectrometry
•
Western Blotting
•
Bioassay MARKET BY TYPES
• o
Recombinant Non-Glycosylated Protein Human Growth Hormone
o
Insulin
o
Interferon
o
Granulocyte colony stimulating factor (G-CSF)
o
Others
•
Recombinant Glycosylated Protein
o
Erythropoietin
o
Monoclonal antibodies
o
Others
•
Peptides
o
Octreotide
o
Desmopressin
o
Cyclosporine
o
Calcitonin
o
Eptifibatide
o
LH-RH (Leuprolide)
o
Nesiritide
o
Teriparatide
o
Bivalirudin
o
Enfuvirtide
o
Glucagon MARKET BY APPLICATIONS
• o
Blood disorders Chemotherapy induce Anaemia
o
Hemophilia
o
Pulmonary embolism
•
Oncology diseases
o
Lungs cancer
o
Colorectal cancer
o
Breast cancer
o
Cervical cancer
o
Leukemia
o
Prostate cancer
•
Chronic and autoimmune diseases
o
Neutropenia
o
Multiple sclerosis
o
Cystic Fibrosis
o
Rheumatoid arthritis (RA)
o
Acromegaly
o
Leprosy
•
Growth hormone deficiencies
•
Others MARKET BY SERVICES
• •
Contract Research and Manufacturing Services (CRAMS) Clinical Trials MARKET BY GEOGRAPHY
• •
North America Europe
•
Asia-Pacific
•
LAMEA About Us Allied Market Research is a Global service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view to provide
business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Contact: Sona Padman 5320 SW Macadam Avenue, Suite 100, Portland, OR 97239, United States. Direct: +1 (617) 674-4143 Toll Free: +1 (855) 711-1555 Fax: +1 (855) 550-5975 Email: sales@alliedmarketresearch.com